Pallidotomi Sonrası Dopamin Disregülasyon Sendromu Gelişen Parkinson Hastası: Olgu Sunumu

Year 2014, Volume: 15 Issue: 3, 312 - 315, 01.12.2014

Suat Kamışlı Ebru Öztoprak Özden Kamışlı Sibel Altınayar Cemal Özcan

Abstract

Dopamine dysregulation syndrome (DDS), is a rare complication of long-term dopamine replacement therapy (DRT) in Parkinson Disease. Patients who developed DDS, require higher amounts of dopaminergic drugs than usual to control motor symptoms. Dopamine dysregulation syndrome may appear after deep brain stimulation of the subthalamic nucleus or globus pallidus internus, listed in the literature. In this report we discussed a case of DDS after pallidotomy

Keywords

Parkinson disease; pallidotomy; dopamine replacement treatment; dopamine dysregulation syndrome; psychosis

Pallidotomi Sonrası Dopamin Disregülasyon Sendromu Gelişen Parkinson Hastası: Olgu Sunumu

Abstract

Dopamin disregülasyon sendromu (DDS), Parkinson hastalarında görülen, uzun dönem dopamin replasman tedavisinin (DRT) nadir bir komplikasyonudur. DDS gelişen hastalar, motor semptomlarını kontrol altına almak için gerekenden daha fazla miktarda dopaminerjik ilacı kompulsif olarak kullanmaktadırlar. DDS’nun, subtalamik nükleus veya globus pallidus internusa yönelik nörostimülasyon ameliyatları sonrasında da ortaya çıkabileceği literatürde belirtilmiştir. Bu sunumda pallidotomi sonrası DDS gelişen olguyu tartıştık

Keywords

Parkinson hastalığı; pallidotomi; dopamin replasman tedavisi; dopamin disregülasyon sendromu; psikoz

References

• Giovannoni G, O'Sullivan JD, Turner K, Manson AJ,
• Lees AJ. Hedonistic homeostatic dysregulation in
• patients with Parkinson's disease on dopamine
• replacement therapies. J Neurol Neurosurg Psychiatry 2000;68(4):423-8.
• Pezzella FR, Colosimo C, Vanacore N et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005;20(1):77-81.
• Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson’s disease. Curr OpinNeurol 2004;17(4):393-8.
• Bonci A, Singh V. Dopamine dysregulation syndrome in parkinson’s disease patients: from reward to penalty. Annals of Neurol 2006;59(5):733- 4.
• O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23(2):157-70.
• Schwingenschuh P, Katschnig P, Saurugg R, Ott E, Bhatia KP. Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? Mov Disord 2010;25(4):493-6.
• De la Casa-Fages B, Grandas F. Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurol Res Int 2011;2011:759895.
• Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16(9):1148- 52.
• Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug uselinked to sensitized ventral striatal 2006;59(5):852-8. transmission. Ann
• Neurol 10. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy inParkinson’s disease: reward systems gone awry? Lancet Neurol 2003;2(10):595–604.
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73. 12. Katzenschlager R. Dopaminergic dysregulation syndrome in Parkinson's disease. J Neurol Sci 2011;310(1-2):271-5.